Key Takeaways
- • THL Partners closed its flagship fund, THL Equity Fund X LP, at $6.35 billion in capital, marking a 13.4% increase over the firm's prior flagship fund which raised $5.6 billion in October 2021.
- • The fund attracted a globally diversified limited partner base spanning North America, Latin America, Europe, Asia, Australia, and the Middle East, including public and corporate pension funds, sovereign wealth funds, financial institutions, and family offices.
- • THL has now accumulated over $50 billion in total equity capital raised since its founding in 1974, positioning it among the oldest and largest private equity firms in the United States.
- • The firm maintains strategic focus on financial technology and services, healthcare, and technology and business solutions sectors, with recent activity including the acquisition of Celerion, a clinical research services provider, from H.I.G. Capital.
Summary
THL Partners has successfully closed its latest flagship fund at $6.35 billion, demonstrating continued institutional confidence in the Boston-based private equity firm. The capital raise for THL Equity Fund X LP exceeded the previous flagship fund's performance, which closed in October 2021 with $5.6 billion. The new fund achieved strong commitments from a broad coalition of institutional investors, reflecting the firm's established track record and platform capabilities.
The limited partner composition reflects institutional diversification across geographies and investor types. The fund attracted capital from public and corporate pension funds, sovereign wealth funds, financial institutions, and family offices distributed across major global regions including North America, Latin America, Europe, Asia, Australia, and the Middle East. This geographic and institutional diversity positions Fund X to support THL's investment strategy across multiple markets and sectors.
The fund close represents a significant milestone for THL's capital accumulation history. Since its founding in 1974, THL has raised more than $50 billion in total equity capital, underscoring its position as one of the oldest and most established private equity investment firms in the United States. Scott Sperling, co-chief executive of THL, emphasized the firm's value of long-term partnerships and the collaborative benefits enabled across its platform.
THL's investment thesis remains focused on financial technology and services, healthcare, and technology and business solutions. Recent activity demonstrates this strategic focus through the firm's acquisition of Celerion, a Nebraska-based clinical research services company previously held by H.I.G. Capital. Celerion specializes in early-stage clinical pharmacology work, conducting initial human testing, safety assessments, and drug interaction studies critical to regulatory approval processes for new therapeutics.
The limited partner composition reflects institutional diversification across geographies and investor types. The fund attracted capital from public and corporate pension funds, sovereign wealth funds, financial institutions, and family offices distributed across major global regions including North America, Latin America, Europe, Asia, Australia, and the Middle East. This geographic and institutional diversity positions Fund X to support THL's investment strategy across multiple markets and sectors.
The fund close represents a significant milestone for THL's capital accumulation history. Since its founding in 1974, THL has raised more than $50 billion in total equity capital, underscoring its position as one of the oldest and most established private equity investment firms in the United States. Scott Sperling, co-chief executive of THL, emphasized the firm's value of long-term partnerships and the collaborative benefits enabled across its platform.
THL's investment thesis remains focused on financial technology and services, healthcare, and technology and business solutions. Recent activity demonstrates this strategic focus through the firm's acquisition of Celerion, a Nebraska-based clinical research services company previously held by H.I.G. Capital. Celerion specializes in early-stage clinical pharmacology work, conducting initial human testing, safety assessments, and drug interaction studies critical to regulatory approval processes for new therapeutics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.